Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients
- Document Type
- Publications · Journal Article
- Registered DB
- SCIEScopus
- Journal Ranking
- JCR Q1Scopus Q1
- Journal
- EUROPEAN JOURNAL OF CANCER49(2) · pp.403 · 2013
- Citation
- Web of Science 25
- JCR IF
- JCR 2012 5.061
- ISSN
- 0959-8049
Authors
- Kim, Kyung ImFirst authorCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, South Korea
- Huh, Ik-SooDepartment of Statistics, Seoul National University, South Korea
- Kim, In-WhaCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, South Korea
- Park, TaesungDepartment of Statistics, Seoul National University, South Korea
- Ahn, Kwang-SungClinical Research Institute, Seoul National University Hospital, South Korea
- Yoon, Sung-SooClinical Research Institute, Seoul National University Hospital, South Korea
- Yoon, Jeong-HyunCollege of Pharmacy, Pusan National University, South Korea
- Oh, Jung MiCorresponding authorCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, South Korea
Abstract
Cytarabine arabinoside (ara-C) is the key agent for treating acute myeloid leukaemia (AML). Here, we genotyped 139 single nucleotide polymorphisms (SNPs) within the araC transport and metabolic pathway using the Illumina Golden Gate Assay in 97 patients with previously non-treated de novo AML other than M3. DCK rs4694362 (CC genotype) was a significant poor prognostic factor for overall survival (OS) (hazard ratio [HR], 33.202 [95% confidence interval (CI), 4.937-223.273], P < 0.0001, P-Bonferroni = 0.017). SLC29A1 rs3734703 (AA or AC genotype) in combination with TYMS rs2612100 (AA genotype) was significantly associated with shorter relapse free survival (RFS) (HR, 17.630 [95% CI, 4.829-64.369], P < 0.0001, P-Bonferroni = 0.021). These SNPs showed moderate or large inter-ethnic divergence in allele frequencies from African or Caucasian populations. The results of our study suggest that a single SNP and SNP-SNP interactions may help to predict the drug response and provide a guide in developing individualised chemotherapy for AML patients receiving ara-C based chemotherapy. (C) 2012 Elsevier Ltd. All rights reserved.
Keywords
Acute myeloid leukaemiaSingle nucleotide polymorphismSNP-SNP interactionCytarabineResponseEthnicitySINGLE-NUCLEOTIDE POLYMORPHISMARA-C SENSITIVITYDEOXYCYTIDINE KINASECYTOSINE-ARABINOSIDE1-BETA-D-ARABINOFURANOSYLCYTOSINETHYMIDINEEXPRESSIONSURVIVALTHERAPYCELLS
Identifiers
- WoS UID
- 000313193000016



Login
Back to Publication list